Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.58 |
| ▸ | PKM | P14618 | 1/20 | 0.58 |
| ▸ | KDM1A | O60341 | 19/20 | 0.57 |
| ▸ | MAOB | P27338 | 3/20 | 0.57 |
| ▸ | HDAC6 | Q9UBN7 | 8/20 | 0.52 |
| ▸ | DRD2 | P14416 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15425023 | 1.00 | KDM4E (0.58) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL15411011 | 1.00 | KDM4E (0.58) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL12965573 | 1.00 | KDM4E (0.58) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL12813366 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL21101170 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL19513593 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL12965568 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL21100965 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL12813368 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 | |
| SCHEMBL12813626 | 0.96 | KDM4E (0.62) | KDM4EPKMKDM1AMAOBHDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | claimed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | claimed |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2026-03-17 | — | — | US | disclosed |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-10-17 | — | — | US | disclosed |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | ISTITUTO EUROPEO DI ONCOLOGIA S.R.L. (IT) | 2024-03-05 | — | — | US | disclosed |
| EP-2688568-B1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE IP NO 2 LTD (GB) | 2019-06-19 | — | — | EP | disclosed |
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-09-04 | — | — | US | disclosed |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2018-01-04 | — | — | US | disclosed |
| US-9795597-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2017-10-24 | — | — | US | disclosed |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2016-08-04 | — | — | US | disclosed |
| US-9346840-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2016-05-24 | — | — | US | disclosed |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) | 2014-12-18 | — | — | US | disclosed |
| US-8853408-B2 | Cyclopropylamines as LSD1 inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) | 2014-10-07 | — | — | US | disclosed |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | Glaxo Smith Kline LLC | 2014-01-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10064854-B2 | Cyclopropylamines as LSD1 inhibitors | KDM1B, KDM1A, KDM3B | KDM4E 13/4885PKM 739/4885KDM1A 2/4885 |
| US-20160220547-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4E 13/4885PKM 739/4885KDM1A 2/4885 |
| US-20140018393-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4E 13/4885PKM 739/4885KDM1A 2/4885 |
| US-11918580-B2 | Use of a combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK6, KDM1B, KDM6B | KDM4E 18/4885PKM 719/4885KDM1A 7/4885 |
| US-12576083-B2 | Combinational therapy of LSD1 inhibitors with P21 activators in the treatment of cancer | CDK3, CDKN1A, CDKL3 | KDM4E 69/4885PKM 1268/4885KDM1A 26/4885 |
| US-20180000805-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4E 13/4885PKM 739/4885KDM1A 2/4885 |
| US-20240342178-A1 | COMBINATIONAL THERAPY OF LSD1 INHIBITORS WITH P21 ACTIVATORS IN THE TREATMENT OF CANCER | KDM1B, DOT1L, EZH2 | KDM4E 27/4885PKM 914/4885KDM1A 10/4885 |
| US-20140371176-A1 | CYCLOPROPYLAMINES AS LSD1 INHIBITORS | KDM1B, KDM1A, KDM3B | KDM4E 13/4885PKM 739/4885KDM1A 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.